Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program.
Liu
Gordon G
GG
Department of Health Economics and Management, Peking University Guanghua School of Management, Beijing, China.
Sun
Shawn X
SX
Christensen
Dale B
DB
Zhao
Zhongyun
Z
D000328:Adult; D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D008484:Medicaid / Q000191:economics*; D008875:Middle Aged; D009657:North Carolina; D000077152:Olanzapine; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use; D012559:Schizophrenia / Q000191:economics* / Q000628:therapy*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine